Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
Provided By GlobeNewswire
Last update: May 13, 2025
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June
Read more at globenewswire.com
